Newron Completes Enrollment in Phase 3 Evenamide Trial for Treatment-Resistant Schizophrenia

• Newron Pharmaceuticals completed enrollment in its pivotal Phase 3 ENIGMA-TRS 1 trial of evenamide for treatment-resistant schizophrenia on October 22, 2026.
• The trial randomized 618 patients to evaluate evenamide as an add-on to second-generation antipsychotics.
• Topline 12-week results are expected in the first quarter of 2027; the double-blind, placebo-controlled study will continue through 52 weeks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Newron Pharmaceuticals S.p.A. published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2419974_en) on October 22, 2026, and is solely responsible for the information contained therein.